Medical Device Submissions Guidebook: 510(k) & De Novo

Enjoy this new in-depth resource with timely and expert guidance on the 510(k) and De Novo submission process! The comprehensive guide will help regulatory professionals navigate the complexities of the 510(k) and De Novo submission processes as they bring their organizations latest technologies to market.
Starting at $200 for AdvaMed® members and packed with expert insights, best practices, and step-by-step guidance, this Guidebook will help streamline your submissions application, avoid common pitfalls, and ensure compliance with FDA requirements. Access the Guidebook today!
Related Reading
Resource / Diagnostics / Regulatory Affairs
Clinical Evidence for IVD Medical Devices
May 22, 2026
AdvaMed’s feedback on the CEIVD draft outlines targeted recommendations to improve clarity in clinical evidence expectations for IVD devices, including more precise terminology, alignment with global frameworks, and clearer distinctions between real-world data and evidence.
News / Regulatory Affairs
AdvaMed® Welcomes Senate Introduction of Bipartisan Medical Device Electronic Labeling Bill
May 14, 2026
Washington, D.C.—AdvaMed, the Medtech Association, the world’s biggest trade association representing medtech innovators, welcomed Senate introduction of the bipartisan Medical Device Electronic Labeling Act (S. 4519), which would allow medtech instructions for use to be provided electronically, with paper copies being available upon request.
News / Regulatory Affairs / Small Business
Bright Uro Receives FDA Clearance for Glean® Abdominal Sensor
May 8, 2026
IRVINE, Calif., May 7, 2026 /PRNewswire/ — Bright Uro, a medical device company with a mission to transform care for lower urinary tract dysfunction (LUTD) through innovations in urodynamics, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Glean® Abdominal Sensor. This new sensor expands the capabilities of the Glean® Urodynamics System to include multi-channel urodynamic studies. This comprehensive system enables wireless, catheter-free ambulatory urodynamics designed to support clinical decision making for patients with LUTD and other urological conditions.
News / Regulatory Affairs
i-GENTIC AI Expands GENIE to Enforce Full FDA Compliance Lifecycle for Life Sciences
May 4, 2026
PALO ALTO, CA, UNITED STATES, May 4, 2026 / EINPresswire.com / — Biopharma and medtech companies face a years-long process to get their products approved. Drug and device makers navigate a full spectrum of FDA and global regulatory frameworks to move innovation forward.
Blog / Coverage & Payment / Government & Legislative Affairs / Health Access / Regulatory Affairs
A Policy Win for Maternal Health Innovation Through FDA–CMS Collaboration
April 27, 2026
The United States faces a maternal health crisis demanding urgent action. The U.S. has the worst maternal outcomes among high income nations. Our maternal mortality rates far exceed peer countries’, despite the highest per capita health care spending. Protecting mothers and improving birth outcomes provides an important opportunity for bipartisan priority leadership.
Event / Regulatory Affairs
Compliance Considerations in an Active Deals Market for Medtech
June 17, 2026
11:00 AM – 12:00 PM
Join PwC to explore how compliance leaders can proactively support deal activity across the transaction lifecycle.
Event / Digital Health / Regulatory Affairs
AdvaMed® Cybersecurity Summit
November 10, 2026
Join cyber experts for the 2026 Cybersecurity Summit to address the latest industry issues and FDA requirements.
News / Regulatory Affairs / Small Business
Carbon Medical Technologies’ InjecSURE® Injection System Receives FDA 510(k) Clearance, Expanding CMT’s Portfolio of Urology Delivery Solutions
April 16, 2026
Saint Paul, MN – April 15, 2026. Carbon Medical Technologies, Inc. (CMT), a manufacturer of implantable medical devices and delivery systems utilizing proprietary technologies, is pleased to announce that its InjecSURE® Injection System has received clearance from the U.S. Food and Drug Administration (FDA) through the 510(k) pathway. This milestone marks the introduction of a new accessory system designed to support the delivery of syringe-based injectable materials into urethral tissues during cystoscopic procedures.